On September 3, 2020 MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, reported that the Company’s management will participate in the following investor conferences in September (Press release, MacroGenics, SEP 3, 2020, View Source [SID1234564388]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 15th Annual BioPharma Virtual Conference. MacroGenics’ management will participate in one-on-one meetings and present in the "Novel Antibodies and Protein Therapeutics in Oncology" panel on September 10, 2020 at 10:45 AM ET.
HC Wainwright & Co. 22nd Annual Global Investment Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on September 14, 2020 at 10:00 AM ET.
Cantor Virtual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and provide a corporate overview on September 16, 2020 at 8:00 AM ET.
Morgan Stanley 18th Annual Global Healthcare Conference. MacroGenics’ management will participate in one-on-one meetings and a fireside chat on September 17, 2020 at 2:45 PM ET.
Webcasts of each presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics’ website at View Source The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.

On September 3, 2020 Bio-Techne Corporation (NASDAQ:TECH) reported that Chuck Kummeth, President and Chief Executive Officer, will present at the 2020 Wells Fargo Virtual Healthcare Conference on Wednesday, September 9, 2020 at 11:20 a.m. EDT (Press release, Bio-Techne, SEP 3, 2020, View Sourcenews/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference" target="_blank" title="View Sourcenews/detail/207/bio-techne-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference" rel="nofollow">View Source [SID1234564387]). A live webcast of the presentation can be accessed via Bio-Techne’s Investor Relations website at View Source or through the following link (webcast).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 3, 2020 Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported that the Company will present at two upcoming virtual investor conferences (Press release, Sunesis, SEP 3, 2020, View Source [SID1234564386]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 2020 Virtual Healthcare Conference
Date: Thursday, September 10
Time: 2:00 PM Eastern Time

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Tuesday, September 21
Time: 4:10 PM Eastern Time

Live webcasts of the events will be available on the Sunesis website at View Source A replay of each will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

On September 3, 2020 Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported that management will participate in the following virtual investor conferences in September (Press release, Bicycle Therapeutics, SEP 3, 2020, View Source [SID1234564385]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020
Goldman Sachs 10th Annual Biotech Symposium on Friday, September 11, 2020
H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14, 2020; presentation at 1:00 p.m. ET
Cantor Global Healthcare Conference on Wednesday, September 16, 2020; presentation at 9:20 a.m. ET
Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Monday, September 21, 2020; presentation at 10:50 a.m. ET
A live webcast of each presentation will be accessible in the Investors & Media section of Bicycle’s website at www.bicycletherapeutics.com. Archived replays of the webcasts will be available for 90 days following the presentation dates.

On September 3, 2020 On August 28, 2020, Mersana Therapeutics, Inc. (the "Company") reported that it has entered into a second amendment (the "Amendment") to its existing loan and security agreement (as amended prior to the Amendment, the "Existing Credit Facility") with Silicon Valley Bank ("SVB") (Filing, 8-K, Mersana Therapeutics, SEP 3, 2020, sec.gov/ix?doc=/Archives/edgar/data/1442836/000110465920102013/tm2030113-1_8k.htm [SID1234564384]). Pursuant to the Amendment, the Company may borrow, at its option, (i) up to $25.0 million, in up to five principal advances through April 30, 2022, and (ii) an additional $5.0 million, in one principal advance, if the Company reaches certain development milestone events, as described in in the Amendment, through April 30, 2022. The Company drew $5.2 million upon execution of the Amendment, the proceeds of which were used to repay the Company’s existing balance and satisfy its obligations to SVB under the Existing Credit Facility. Pursuant to the Amendment, among other things, the end of the interest-only payment period, as described in the Amendment, is extended from August 31, 2020, to May 31, 2022, and the Company is no longer required to maintain a minimum liquidity ratio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!